| Identification | Back Directory | [Name]
β-D-Glucopyranosiduronic acid, 2-[[4-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)benzoyl]amino]-3-[(4-methoxybenzoyl)amino]phenyl | [CAS]
432029-12-4 | [Synonyms]
YM222714
YM-222714
YM 222714
Darexaban glucuronide
β-D-Glucopyranosiduronic acid, 2-[[4-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)benzoyl]amino]-3-[(4-methoxybenzoyl)amino]phenyl | [Molecular Formula]
C33H38N4O10 | [MOL File]
432029-12-4.mol | [Molecular Weight]
650.69 |
| Hazard Information | Back Directory | [Description]
Darexaban glucuronide, also known as YM-222714, is the major component in plasma after oral administration of darexaban to humans and is the pharmacologically active metabolite. Darexaban (YM150) is a direct inhibitor of factor Xa. It is an experimental drug that acts as an anticoagulant and antithrombotic to prevent venous thromboembolism after a major orthopaedic surgery, stroke in patients with atrial fibrillation and possibly ischemic events in acute coronary syndrome. It is used in form of the maleate. The development of darexaban was discontinued in September 2011. | [Uses]
Darexaban glucuronide (YM-222714) is a active metabolite of darexaban (YM150). Darexaban glucuronide has an oral activity and antithrombotic effect[1]. | [References]
[1] "Yoshiyuki Iwatsuki, et al. Biochemical and pharmacological profile of darexaban, an oral direct factor Xa inhibitor. Eur J Pharmacol. 2011 Dec 30;673(1-3):49-55.
." DOI:10.1016/j.ejphar.2011.10.009 |
|
|